Oryzon Genomics (ORY): Planning Iadademstat's Path to Market
Oryzon is advancing its epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications. The company focuses on rapid, small trials for proof-of-concept data. Recent insights have led to plans for new pivotal trials with iadademstat. The updated valuation stands at €739 million or €13.9 per share, an increase from €591 million or €11.1 per share previously. Key indications include AML, SCLC, Alzheimer's, and bipolar disorder, while schizophrenia has been added as a new opportunity.
- Increased valuation to €739 million or €13.9 per share, up from €591 million or €11.1 per share.
- Plans for at least two new pivotal trials for iadademstat, indicating potential market advancements.
- Diverse R&D pipeline with major indications including AML, SCLC, Alzheimer's, and bipolar disorder.
- Removed multiple sclerosis indication from the R&D pipeline, which may reduce potential market opportunities.
LONDON, UK / ACCESSWIRE / February 10, 2022 / Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific demethylase 1A, or LSD1, inhibitors). The company's R&D strategy has been to select indications where there is a scientific rationale for intervention with an epigenetic therapy and then conduct quick and relatively small trials, but with patient sample sizes still sufficient to obtain proof-of-concept data. With this strategy, Oryzon has completed multiple trials over the last several years. Importantly, insights from the data have allowed the company to design the next phase of development. At least two new trials with iadademstat could potentially be pivotal. Our valuation is €739m, or €13.9 per share (vs €11.1 per share previously).
Our valuation is higher at €739m, or €13.9 per share, versus €591m or €11.1/share previously. Oryzon's R&D pipeline has evolved substantially over the last several months. Accordingly, we have extensively revised our rNPV model. In our rNPV model we keep AML (
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Jonas Peciulis +44 (0)20 3077 5728 healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/688022/Oryzon-Genomics-ORY-Planning-Iadademstats-Path-to-Market
FAQ
What is Oryzon's current valuation and share price according to the recent press release?
What pivotal trials are planned for iadademstat?
What indications constitute Oryzon's R&D pipeline?
What changes were made to Oryzon's R&D strategy?
